NO316889B1 - Vannfri krystallform av R(-)-N-(4,4-di(3-metyltien-2-yl)but-3-enyl) -nipekotinsyrehydrokloridet, fremgangsmate for fremstilling derav, farmasoytisk preparat som omfatter et slikt krystallinsk salt, og anvendelse av et slikt krystallinsk salt til fremstill - Google Patents
Vannfri krystallform av R(-)-N-(4,4-di(3-metyltien-2-yl)but-3-enyl) -nipekotinsyrehydrokloridet, fremgangsmate for fremstilling derav, farmasoytisk preparat som omfatter et slikt krystallinsk salt, og anvendelse av et slikt krystallinsk salt til fremstill Download PDFInfo
- Publication number
- NO316889B1 NO316889B1 NO19985809A NO985809A NO316889B1 NO 316889 B1 NO316889 B1 NO 316889B1 NO 19985809 A NO19985809 A NO 19985809A NO 985809 A NO985809 A NO 985809A NO 316889 B1 NO316889 B1 NO 316889B1
- Authority
- NO
- Norway
- Prior art keywords
- crystalline salt
- methylthien
- enyl
- hydrochloride
- crystal form
- Prior art date
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims description 36
- 239000013078 crystal Substances 0.000 title claims description 15
- 238000000034 method Methods 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title claims description 9
- 150000003839 salts Chemical class 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title description 4
- -1 4,4-di (3-methylthien-2-yl) but-3-enyl Chemical group 0.000 title description 3
- 239000002253 acid Substances 0.000 title description 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- YUKARLAABCGMCN-PKLMIRHRSA-N tiagabine hydrochloride Chemical compound Cl.C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C YUKARLAABCGMCN-PKLMIRHRSA-N 0.000 claims description 19
- 229960002410 tiagabine hydrochloride Drugs 0.000 claims description 19
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 7
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 150000004682 monohydrates Chemical group 0.000 description 5
- 238000001914 filtration Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- KOZCGZMZXXVHCF-GGMCWBHBSA-N (3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid hydrate hydrochloride Chemical compound O.Cl.C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C KOZCGZMZXXVHCF-GGMCWBHBSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- NSGCWILIYQUGIO-GOSISDBHSA-N ethyl (3r)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylate Chemical compound C1[C@H](C(=O)OCC)CCCN1CCC=C(C1=C(C=CS1)C)C1=C(C)C=CS1 NSGCWILIYQUGIO-GOSISDBHSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 229960001918 tiagabine Drugs 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- YUKARLAABCGMCN-UHFFFAOYSA-N 1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid;hydrochloride Chemical compound Cl.C1=CSC(C(=CCCN2CC(CCC2)C(O)=O)C2=C(C=CS2)C)=C1C YUKARLAABCGMCN-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- CJQWLNNCQIHKHP-UHFFFAOYSA-N Ethyl 3-mercaptopropanoic acid Chemical compound CCOC(=O)CCS CJQWLNNCQIHKHP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK66196 | 1996-06-14 | ||
| PCT/DK1997/000244 WO1997047619A1 (en) | 1996-06-14 | 1997-06-03 | Modified form of the r(-)-n-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO985809L NO985809L (no) | 1998-12-11 |
| NO985809D0 NO985809D0 (no) | 1998-12-11 |
| NO316889B1 true NO316889B1 (no) | 2004-06-14 |
Family
ID=8096101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19985809A NO316889B1 (no) | 1996-06-14 | 1998-12-11 | Vannfri krystallform av R(-)-N-(4,4-di(3-metyltien-2-yl)but-3-enyl) -nipekotinsyrehydrokloridet, fremgangsmate for fremstilling derav, farmasoytisk preparat som omfatter et slikt krystallinsk salt, og anvendelse av et slikt krystallinsk salt til fremstill |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0906309B1 (cs) |
| JP (1) | JP2000511909A (cs) |
| CN (1) | CN1636565A (cs) |
| AR (1) | AR008236A1 (cs) |
| AT (1) | ATE223405T1 (cs) |
| AU (1) | AU723267B2 (cs) |
| BR (1) | BR9709725A (cs) |
| CZ (1) | CZ295578B6 (cs) |
| DE (1) | DE69715196T2 (cs) |
| DK (1) | DK0906309T3 (cs) |
| ES (1) | ES2181002T3 (cs) |
| HU (1) | HUP9904035A3 (cs) |
| IL (1) | IL127469A (cs) |
| NO (1) | NO316889B1 (cs) |
| PL (1) | PL190858B1 (cs) |
| PT (1) | PT906309E (cs) |
| RU (1) | RU2177478C2 (cs) |
| UA (1) | UA52661C2 (cs) |
| WO (1) | WO1997047619A1 (cs) |
| ZA (1) | ZA975266B (cs) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5914333A (en) * | 1996-07-31 | 1999-06-22 | Novo Nordisk A/S | Treatment of psychotic disorders |
| IE970588A1 (en) | 1997-08-01 | 2000-08-23 | Elan Corp Plc | Controlled release pharmaceutical compositions containing tiagabine |
| WO1999006045A1 (en) * | 1997-08-01 | 1999-02-11 | Elan Corporation, Plc | Controlled release pharmaceutical compositions containing tiagabine |
| CN1314684C (zh) * | 2003-12-24 | 2007-05-09 | 中国科学院上海有机化学研究所 | 噻加宾及其消旋体和s－构型的合成方法及其无定形粉末的制法 |
| GB0402118D0 (en) * | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| WO2005092886A1 (en) * | 2004-03-29 | 2005-10-06 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous form of tiagabine |
| US20080064727A1 (en) * | 2006-08-18 | 2008-03-13 | Cephalon, Inc. | Crystalline forms of tiagabine hydrochloride |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK288385D0 (da) * | 1985-06-26 | 1985-06-26 | Novo Industri As | Aminosyrederivater |
| DK58291D0 (da) * | 1991-04-02 | 1991-04-02 | Novo Nordisk As | Krystalinsk stof og dets fremstilling |
-
1997
- 1997-03-06 UA UA98126589A patent/UA52661C2/uk unknown
- 1997-06-03 DK DK97927006T patent/DK0906309T3/da active
- 1997-06-03 WO PCT/DK1997/000244 patent/WO1997047619A1/en active IP Right Grant
- 1997-06-03 AT AT97927006T patent/ATE223405T1/de active
- 1997-06-03 DE DE69715196T patent/DE69715196T2/de not_active Expired - Lifetime
- 1997-06-03 EP EP97927006A patent/EP0906309B1/en not_active Expired - Lifetime
- 1997-06-03 BR BR9709725A patent/BR9709725A/pt not_active IP Right Cessation
- 1997-06-03 PT PT97927006T patent/PT906309E/pt unknown
- 1997-06-03 ES ES97927006T patent/ES2181002T3/es not_active Expired - Lifetime
- 1997-06-03 HU HU9904035A patent/HUP9904035A3/hu unknown
- 1997-06-03 PL PL330424A patent/PL190858B1/pl unknown
- 1997-06-03 CZ CZ19984019A patent/CZ295578B6/cs not_active IP Right Cessation
- 1997-06-03 CN CNA2004100926232A patent/CN1636565A/zh active Pending
- 1997-06-03 AU AU31653/97A patent/AU723267B2/en not_active Expired
- 1997-06-03 RU RU99100703/04A patent/RU2177478C2/ru not_active IP Right Cessation
- 1997-06-03 JP JP10501077A patent/JP2000511909A/ja not_active Ceased
- 1997-06-03 IL IL12746997A patent/IL127469A/xx not_active IP Right Cessation
- 1997-06-13 ZA ZA9705266A patent/ZA975266B/xx unknown
- 1997-06-13 AR ARP970102614A patent/AR008236A1/es active IP Right Grant
-
1998
- 1998-12-11 NO NO19985809A patent/NO316889B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0906309A1 (en) | 1999-04-07 |
| ATE223405T1 (de) | 2002-09-15 |
| PL330424A1 (en) | 1999-05-10 |
| NO985809L (no) | 1998-12-11 |
| AU3165397A (en) | 1998-01-07 |
| RU2177478C2 (ru) | 2001-12-27 |
| AR008236A1 (es) | 1999-12-29 |
| ZA975266B (en) | 1998-02-04 |
| DE69715196T2 (de) | 2003-05-15 |
| DE69715196D1 (de) | 2002-10-10 |
| WO1997047619A1 (en) | 1997-12-18 |
| JP2000511909A (ja) | 2000-09-12 |
| DK0906309T3 (da) | 2002-12-16 |
| EP0906309B1 (en) | 2002-09-04 |
| IL127469A (en) | 2001-01-11 |
| ES2181002T3 (es) | 2003-02-16 |
| HUP9904035A3 (en) | 2000-07-28 |
| HUP9904035A2 (hu) | 2000-05-28 |
| UA52661C2 (uk) | 2003-01-15 |
| IL127469A0 (en) | 1999-10-28 |
| NO985809D0 (no) | 1998-12-11 |
| BR9709725A (pt) | 1999-08-10 |
| PL190858B1 (pl) | 2006-02-28 |
| CN1636565A (zh) | 2005-07-13 |
| CZ295578B6 (cs) | 2005-08-17 |
| CZ401998A3 (cs) | 1999-06-16 |
| AU723267B2 (en) | 2000-08-24 |
| PT906309E (pt) | 2002-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5958951A (en) | Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride | |
| DK172076B1 (da) | Derivater af 4-benzyl-1-(2H)-phthalazinon, fremgangsmåde til fremstilling heraf, forbindelserne til terapeutisk anvendelse, anvendelse af forbindelserne til fremstilling af lægemidler, lægemidler indeholdende forbindelserne samt fremgangsmåde til fremstilling af sådanne lægemidler | |
| US20050267162A1 (en) | Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione | |
| US6391906B2 (en) | Crystals of celecoxib | |
| NO320014B1 (no) | Ny krystallinsk form for omeprazol, fremgangsmate for fremstilling derav, omeprazolsammensetning, farmasoytisk formulering samt anvendelse av omeprazolformen. | |
| EP0579681B1 (en) | Crystalline tiagabine hydrochloride monohydrate, its preparation and use | |
| FR2883285A1 (fr) | Sel besylate de la 7-(2-(4-(3-trifluoromethyl-phenyl) -1,2,3,6-tetrahudro-pyrid-1-yl)ethyl) isoquinoleine, sa preparation et son utilisation en therapeutique | |
| NO316889B1 (no) | Vannfri krystallform av R(-)-N-(4,4-di(3-metyltien-2-yl)but-3-enyl) -nipekotinsyrehydrokloridet, fremgangsmate for fremstilling derav, farmasoytisk preparat som omfatter et slikt krystallinsk salt, og anvendelse av et slikt krystallinsk salt til fremstill | |
| US20060100432A1 (en) | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione | |
| BE1014454A6 (nl) | Amlodipinehemimaleaat. | |
| US6071916A (en) | HIV protease inhibitor | |
| CA2257931C (en) | Modified form of the r(-)-n-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride | |
| KR100491636B1 (ko) | R(-)-n-[4,4-디(3-메틸티엔-2-일)부트-3-엔일)-니페코트산염산염의변형된형태 | |
| US6452007B1 (en) | Crystal forms of 1-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazine | |
| WO2024125361A1 (zh) | N-取代苯基磺酰胺类化合物的固体形式 | |
| AU2001100436A4 (en) | Amlodipine hemimaleate | |
| CZ182895A3 (en) | Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide per se and for treating diseases, and pharmaceutical composition based thereon | |
| JPH03197463A (ja) | 新規ベンズアゼピン | |
| CA2291086A1 (en) | Sulfate salt of an hiv protease inhibitor having an improved oral absorption and bioavailability | |
| WO2019092752A2 (en) | Novel salt of lenalidomide and polymorphic forms thereof | |
| JP3001975B2 (ja) | 結晶性チアガビン塩酸塩−水和物、その製造方法および用途 | |
| NL1018759C1 (nl) | Amlodipinehemimaleaat. | |
| SI21067A2 (sl) | Amlodipin hemimaleat | |
| MXPA99011018A (en) | Sulfate salt of an hiv protease inhibitor having an improved oral absorption and bioavailability | |
| CZ12566U1 (cs) | Amlodipinhemimaleát a farmaceutický prostředek |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |